# Heart Failure, Diuretic Resistance & Volume Management Cardiorenal Syndrome, Neurohormonal Pathophysiology, and Strategies to Overcome Diuretic Resistance Cardiorenal Syndrome Diuretic Resistance Volume Assessment GDMT Escalation Strategies ### Quick Navigation [Cardiorenal Syndrome](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#crs) [Neurohormonal Activation](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#neurohormonal) [Diuretic Resistance](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#diuretic-resistance) [Spot Urine Sodium](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#spot-una) [Escalation Ladder](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#escalation) [Volume Assessment](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#volume) [GDMT in CRS](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#gdmt) [When to Refer](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html#referral) ## Cardiorenal Syndrome: Classification Cardiorenal syndrome (CRS) describes the bidirectional pathophysiologic interactions between the heart and kidneys whereby acute or chronic dysfunction of one organ induces dysfunction of the other. 1 #### Acute Cardiorenal **Heart → Kidney** Acute heart failure (ADHF) causes acute kidney injury *Example:* Cardiogenic shock with AKI; acute decompensated HF with rising creatinine 2 #### Chronic Cardiorenal **Heart → Kidney** Chronic heart failure causes progressive CKD *Example:* Chronic low cardiac output leading to progressive renal dysfunction 3 #### Acute Renocardiac **Kidney → Heart** Acute kidney injury causes acute cardiac dysfunction *Example:* AKI with hyperkalemia causing arrhythmias; volume overload causing pulmonary edema 4 #### Chronic Renocardiac **Kidney → Heart** CKD causes chronic cardiac dysfunction *Example:* CKD causing LVH, accelerated atherosclerosis, cardiomyopathy 5 #### Secondary CRS **Systemic disease → Both** Systemic conditions cause simultaneous cardiac and renal dysfunction *Examples:* Diabetes, sepsis, amyloidosis, sarcoidosis **Clinical Pearl:** Types 1 and 2 (cardiorenal) are most commonly encountered in clinical practice. In Type 1 CRS, the dilemma is whether rising creatinine during ADHF treatment represents worsening renal perfusion (requiring less diuresis) or effective decongestion (allow creatinine to rise while continuing to diurese). Venous congestion, not low cardiac output, is the primary driver of renal dysfunction in most ADHF cases. ## Neurohormonal Activation in Heart Failure Heart failure triggers compensatory neurohormonal responses that initially maintain perfusion but become maladaptive over time, driving disease progression. #### RAAS Activation **Trigger:** Reduced renal perfusion → renin release - Angiotensin II: vasoconstriction, aldosterone secretion, sodium retention - Aldosterone: Na/H₂O retention, K wasting, cardiac fibrosis - Creates positive feedback loop worsening congestion **Therapeutic targets:** ACEi, ARB, ARNI, MRA #### Sympathetic Nervous System **Trigger:** Baroreceptor sensing of low CO - Increased heart rate and contractility - Peripheral vasoconstriction - Renal vasoconstriction (reduced RBF) - Stimulates renin release - Chronic activation: myocyte toxicity, arrhythmias **Therapeutic targets:** Beta-blockers #### ADH / Vasopressin **Trigger:** Non-osmotic release from low effective circulating volume - V2 receptor: water reabsorption in collecting duct - V1a receptor: vasoconstriction - Causes dilutional hyponatremia - Maintains effectiveness even in advanced HF **Clinical marker:** Hyponatremia predicts poor prognosis #### Natriuretic Peptides (BNP/ANP) **Trigger:** Atrial/ventricular wall stretch - Counter-regulatory: natriuresis, vasodilation, RAAS inhibition - Initially protective - **Resistance develops** with disease progression - Receptor downregulation, enhanced degradation by neprilysin **Therapeutic targets:** ARNI (sacubitril/valsartan) **Key Concept:** As HF progresses, BNP loses effectiveness (receptor downregulation, increased neprilysin degradation), while aldosterone and ADH maintain or increase their biological importance. This shifting balance explains why RAAS blockade and MRAs remain effective in advanced HF, while strategies solely enhancing natriuretic peptides show diminishing returns. ## Diuretic Resistance: Mechanisms **Definition:** Failure to achieve adequate decongestion despite escalating diuretic doses. Functionally, an inadequate natriuretic response to appropriate doses of loop diuretics. ### Mechanisms of Diuretic Resistance #### Post-Diuretic Na Retention After diuretic wears off, compensatory Na reabsorption occurs in distal nephron segments, negating earlier natriuresis #### Braking Phenomenon Chronic loop diuretic use causes distal tubular hypertrophy with increased Na/K-ATPase activity and NCC expression, limiting net sodium excretion #### Gut Edema Intestinal wall edema reduces oral furosemide absorption (bioavailability drops from 40–60% to \<20%). Bowel wall thickness correlates with poor oral diuretic response #### Hypoalbuminemia Furosemide is \>95% albumin-bound. Low albumin increases Vd, reduces delivery to proximal tubule OAT for secretion. Most significant when albumin \<2.0 g/dL #### Reduced Renal Perfusion Low cardiac output and/or elevated venous congestion reduce renal blood flow and GFR, decreasing diuretic delivery to tubular site of action #### RAAS Activation Diuretics activate RAAS, which promotes sodium and water retention, partially counteracting diuretic effect ### Gut Edema and Oral Diuretic Failure #### Why Furosemide Fails Orally in ADHF - Baseline oral bioavailability: only 40–60% (highly variable) - Gut wall edema further reduces absorption - Delayed gastric emptying and reduced splanchnic perfusion - Colonic wall thickness ≥3 mm correlates with poor oral response #### Advantages of Bumetanide and Torsemide - **Bumetanide:** 80% oral bioavailability (vs. 40% furosemide); less affected by gut edema due to higher lipid solubility and passive diffusion - **Torsemide:** \>90% bioavailability even in HF, renal insufficiency, and cirrhosis; longest half-life; most predictable absorption - Consider switching from furosemide if poor oral response **Albumin-Furosemide Co-administration:** When albumin \<2.0 g/dL, consider co-administering 25–50g IV albumin with furosemide. Albumin traps furosemide in plasma for delivery to renal OAT transporters. Most effective when albumin \<2.0 g/dL (strong evidence); moderate evidence for 2.0–2.5 g/dL; no benefit when albumin \>2.5 g/dL. Meta-analysis showed +31 mL/hr urine output and +1.76 mEq/hr sodium excretion with co-administration. Effect is maximal at 6–8 hours and diminishes by 24 hours. ## Spot Urine Sodium: Guiding Diuretic Response ### Spot Urine Sodium After IV Furosemide Obtain spot urine Na 1–2 hours after IV loop diuretic administration to assess natriuretic response #### \>70–100 mmol/L Normal natriuretic response *Continue current regimen* #### 50–70 mmol/L Mild resistance *Optimize dose, consider IV* #### 20–50 mmol/L Moderate resistance *Combination diuretics, escalate* #### \<20 mmol/L Severe resistance *SNB, consider UF* **Clinical Pearl:** Spot urine sodium \<50–70 mmol/L after loop diuretic strongly correlates with both diuretic resistance and natriuretic peptide resistance, and predicts poor clinical outcomes. This is a practical bedside tool that avoids the need for 24-hour urine collections. A low spot UNa after adequate loop diuretic dosing is an indication to escalate therapy. ## Escalation Strategy for Diuretic Resistance A stepwise approach to overcoming diuretic resistance. Each step builds on the prior if natriuretic response remains inadequate (spot UNa \<50–70 mmol/L). #### Step 1: Dose Optimization - Convert oral to IV (bypasses gut edema) - IV furosemide: 40–80 mg bolus (naive); up to 200 mg bolus (chronic diuretic use) - Dose must exceed the diuretic threshold to achieve natriuresis - Consider bumetanide or torsemide if furosemide response is poor - Continuous infusion: initial bolus then 5–40 mg/hr furosemide (avoids post-dose reabsorption) #### Step 2: Combination Therapy (Sequential Nephron Blockade) - **Add thiazide:** Metolazone 2.5–10 mg PO or chlorothiazide 250–500 mg IV 30 min before loop diuretic - **Mechanism:** Blocks compensatory Na reabsorption in distal convoluted tubule (addresses braking phenomenon) - **Add MRA:** Spironolactone 25–50 mg to block aldosterone-mediated collecting duct Na retention - **Warning:** Combination therapy causes profound electrolyte losses (K, Mg, Na) — monitor q6–12h #### Step 3: Sequential Nephron Blockade (SNB) — Triple Therapy - Loop diuretic + thiazide + MRA = blockade at 3 nephron segments - Add acetazolamide (250–500 mg IV) for proximal tubule blockade (ADVOR trial: improved decongestion) - Consider IV albumin co-administration if albumin \<2.5 g/dL #### Step 4: Adjunctive Strategies - **Hypertonic saline (3% NaCl):** 150 mL bolus with furosemide; increases renal perfusion pressure and osmotic gradient - **Low-dose dopamine:** 2–5 mcg/kg/min (renal dose); limited evidence but may improve diuretic response - **SGLT2 inhibitors:** Osmotic diuresis via proximal tubule glucosuria; additive to loop diuretics - **Aquaphoresis:** Tolvaptan (V2 antagonist) for hypervolemic hyponatremia; free water clearance without Na loss #### Step 5: Mechanical Fluid Removal - **Ultrafiltration (UF):** Extracorporeal removal of isotonic fluid; bypasses all pharmacologic resistance mechanisms - Indicated when pharmacologic strategies fail or severe cardiorenal syndrome limits diuretic efficacy - CARRESS-HF trial: UF not superior to pharmacologic therapy as first-line and associated with more adverse events - **Peritoneal dialysis:** Consider for chronic refractory fluid overload; gentle, continuous UF - **Hemodialysis/CRRT:** For refractory fluid overload with concurrent severe AKI or ESKD **ADVOR Trial (2022):** Addition of IV acetazolamide 500 mg daily to IV loop diuretics in ADHF improved decongestion at 3 days (42.2% vs 30.5% achieved successful decongestion, RR 1.46, 95% CI 1.17–1.82). Acetazolamide inhibits carbonic anhydrase in the proximal tubule, which indirectly impairs NHE3-mediated sodium reabsorption, thereby increasing Na delivery to the loop of Henle where loop diuretics act. ## Volume Assessment in Heart Failure Accurate assessment of volume status is essential for guiding diuretic therapy. No single parameter is sufficient; integrate multiple data points. | Assessment Tool | What It Tells You | Limitations | |----|----|----| | **JVP (Jugular Venous Pressure)** | Elevated JVP (\>8 cm H₂O) indicates right-sided volume overload and elevated CVP. Most specific bedside sign of congestion. | Difficult in obese patients; requires proper positioning (45 degrees); cannot assess intravascular volume directly | | **BNP / NT-proBNP Trajectory** | Rising = worsening congestion/wall stress; falling = successful decongestion. More useful as a trend than single value. | Affected by obesity (lower), renal failure (higher), age, AF. BNP rises with ARNI (use NT-proBNP instead). Day-to-day variation 15–20%. | | **Daily Weights** | Most practical marker of fluid balance. 1 kg = approximately 1 L fluid. Target 0.5–1 kg/day loss during active decongestion. | Scale accuracy, timing consistency, dietary Na intake affects weight independent of volume | | **Strict I&O** | Net negative fluid balance target during ADHF. Monitors diuretic response quantitatively. | Nursing accuracy variable; insensible losses not captured; cannot distinguish vascular from interstitial fluid removal | | **Spot Urine Sodium** | Post-diuretic UNa \>70 mmol/L indicates adequate natriuretic response. Low UNa (\<50) signals diuretic resistance. | Single time point; requires knowledge of when diuretic was given; dietary Na intake can confound | | **Physical Exam** | Peripheral edema, lung crackles (often absent in chronic HF), hepatomegaly, ascites, S3 gallop, orthopnea | Peripheral edema is a late sign; lung crackles may be absent in chronic compensated HF due to lymphatic drainage adaptation | | **Point-of-Care Ultrasound** | IVC collapsibility (\>50% = likely euvolemic); lung B-lines (correlate with extravascular lung water); pleural effusions | Operator dependent; IVC less reliable with mechanical ventilation or high PEEP | | **Hemoconcentration** | Rising hemoglobin/hematocrit during diuresis suggests effective intravascular volume reduction (plasma water removal exceeds RBC removal) | Confounded by anemia, transfusions, bleeding; insensitive | **Lung Crackles Myth:** Absence of lung crackles does NOT exclude pulmonary congestion in chronic HF. Chronic lymphatic drainage adaptation can clear alveolar fluid even with elevated PCWP. Use BNP trajectory, daily weights, and JVP as more reliable markers of congestion. ## Guideline-Directed Medical Therapy in Cardiorenal Disease The four pillars of HFrEF therapy all have cardiorenal implications. GDMT should be optimized even in the setting of CKD, though dose adjustments may be needed. #### ARNI / ACEi / ARB **Preferred:** ARNI (sacubitril/valsartan) 20% reduction in CV death/HF hospitalization vs. enalapril (PARADIGM-HF) **CKD note:** Dose-adjust for eGFR; ACEi \> ARB for mortality if ARNI unavailable. Monitor K and Cr after initiation. #### Beta-Blocker Carvedilol, metoprolol succinate, bisoprolol Counter SNS overactivation; improve survival **CKD note:** No dose adjustment needed. Avoid initiation during acute decompensation. #### MRA Spironolactone (HFrEF), finerenone (HFpEF/DKD) RALES: 30% mortality reduction; FINEARTS-HF: benefit in HFpEF **CKD note:** nsMRA (finerenone) preferred with eGFR 30–60 due to lower hyperkalemia risk. Monitor K closely. #### SGLT2 Inhibitor Dapagliflozin, empagliflozin Cardiorenal protection in HFrEF, HFpEF, and CKD **CKD note:** Can initiate with eGFR ≥20; continue until dialysis. Hemodynamic benefit occurs within days. Additive diuretic effect. ### Special Considerations in Cardiorenal Disease | Scenario | Approach | |----|----| | **Rising Cr during decongestion** | Often acceptable ("permissive AKI") if the patient is clearly congested. Venous congestion relief may improve renal function. Check if Cr rise is from effective decongestion vs. true renal injury (hemoconcentration suggests the former). | | **Hyperkalemia limiting RAAS blockade** | Consider nsMRA (finerenone) instead of spironolactone; add patiromer or SZC as K binders; SGLT2i may lower K. Do not withhold RAAS blockers reflexively—mortality benefit outweighs mild hyperkalemia risk. | | **Hyponatremia in HF** | Dilutional (hypervolemic) from ADH excess. Restrict free water, optimize decongestion. Tolvaptan for symptomatic hyponatremia. Na \<130 predicts poor prognosis. | | **eGFR \<30 mL/min/1.73m²** | SGLT2i can be initiated down to eGFR 20. ARNI requires dose reduction. Loop diuretics require higher doses (furosemide 80–200 mg IV). Higher doses of thiazides needed (metolazone retains efficacy in advanced CKD). | ## When to Refer to Advanced HF / Mechanical Support Recognize the patient who has exhausted medical options and may benefit from advanced therapies. ### Triggers for Advanced HF Referral - ≥2 HF hospitalizations in 12 months - Progressive decline in eGFR with worsening HF - Need for IV inotropes for hemodynamic support - Persistent NYHA Class III–IV despite optimized GDMT - Peak VO₂ \<14 mL/kg/min on CPET - Rising NT-proBNP despite therapy optimization - Recurrent ICD shocks for ventricular arrhythmias - Diuretic-refractory congestion requiring repeated UF ### Advanced Therapies - **Heart transplantation:** Gold standard for eligible patients; limited by donor availability - **LVAD (Left Ventricular Assist Device):** Bridge to transplant or destination therapy; improves CO and renal perfusion - **Temporary MCS:** Impella, ECMO for cardiogenic shock as bridge to recovery or decision - **Cardiac resynchronization therapy (CRT):** For LBBB with QRS ≥150 ms and EF ≤35% - **Palliative care / hospice:** When advanced therapies are not appropriate; focus on symptom management and quality of life **INTERMACS Profiles:** Advanced HF patients are classified by hemodynamic severity (Profile 1 = critical cardiogenic shock through Profile 7 = advanced NYHA III). Profiles 1–3 warrant urgent advanced HF evaluation. Early referral improves outcomes—do not wait until the patient is INTERMACS 1 (crash and burn). ## References 1. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. *J Am Coll Cardiol*. 2008;52(19):1527-1539. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19007588/) 2. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion. *Eur J Heart Fail*. 2019;21(2):137-155. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30600580/) 3. Felker GM, Ellison DH, Mullens W, et al. Diuretic therapy for patients with heart failure: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2020;75(10):1178-1195. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32164892/) 4. Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload (ADVOR). *N Engl J Med*. 2022;387(13):1185-1195. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36027559/) 5. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome (CARRESS-HF). *N Engl J Med*. 2012;367(24):2296-2304. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23131078/) 6. Boorsma EM, Ter Maaten JM, Voors AA, et al. Renal compression in heart failure: the renal tamponade hypothesis. *JACC Heart Fail*. 2022;10(3):175-183. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35241245/) 7. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). *N Engl J Med*. 2014;371(11):993-1004. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25176015/) 8. Lee TH, Kuo G, Chang CH, et al. Diuretic effect of co-administration of furosemide and albumin: an updated systematic review and meta-analysis. *PLoS One*. 2021;16(12):e0260312. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34851962/) 9. Ikeda Y, Ishii S, Yazaki M, et al. Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure. *ESC Heart Fail*. 2021;8(5):4059-4066. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34323025/) 10. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. *J Am Coll Cardiol*. 2022;79(17):e263-e421. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35379503/) 11. Damman K, Testani JM. The kidney in heart failure: an update. *Eur Heart J*. 2015;36(23):1437-1444. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25838436/) 12. Afsar B, Ortiz A, Covic A, et al. Focus on renal congestion in heart failure. *Clin Kidney J*. 2016;9(1):39-47. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26798459/) **Andrew Bland, MD, FACP, FAAP** \| University of Dubuque PA Program \| Urine Nephrology Now © 2025 \| For educational purposes only ### Also on this topic The same subject at other levels of depth. - **Interactive case:** [Right Heart Failure with Diuretic Resistance](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case17_enhanced.html) --- [Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/hf-diuretic-resistance.html) · Markdown synchronized October 3, 2026.